Additional file 2 of Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Takamizawa, Shigemasa; Shimoi, Tatsunori; Satomi-Tsushita, Natsuko; Yazaki, Shu; Okuya, Toshihiro; Kojima, Yuki; Sumiyoshi-Okuma, Hitomi; Nishikawa, Tadaaki; Tanioka, Maki; Sudo, Kazuki; Noguchi, Emi; Yonemori, Kan

doi:10.6084/m9.figshare.18393324.v1

12885_2021_9112_MOESM2_ESM.docx (17.23 kB)

Additional file 2 of Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

journal contribution

posted on 2022-01-14, 05:07 authored by Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori

Additional file 2. Univariate analyses of overall response rate.

History

Usage metrics

Keywords

Breast cancer Capecitabine Chemotherapy Eribulin Neutrophil-to-lymphocyte ratio NLR Prognostic factor

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 2 of Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

History

Usage metrics

Categories

Keywords

Licence

Exports